{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T11:07:41Z","timestamp":1789211261638,"version":"build-2803163510"},"reference-count":195,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Vaccines and Immunotherapy"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:p>Melanoma has emerged as a major focus of cancer immunotherapy research because of its highly immunogenic nature and responsiveness to immune-based treatments. Therapeutic melanoma vaccines are designed to stimulate tumor-specific immune responses through the delivery of Tumor-Associated Antigens (TAAs), Tumor-Specific Antigens (TSAs), and personalized neoantigens. This narrative review provides an overview of current melanoma vaccine strategies, including peptide-based vaccines, dendritic cell vaccines, nucleic acid-based platforms such as mRNA, DNA, and viral vector vaccines.<\/jats:p>\n                  <jats:p>Recent advances in vaccine engineering and tumor genomics have accelerated the development of personalized neoantigen vaccines capable of targeting mutations unique to individual tumors. In parallel, Artificial Intelligence (AI) and Machine Learning (ML) are increasingly being incorporated into neoantigen identification pipelines to improve epitope prediction and optimize vaccine design. Combination strategies involving Immune Checkpoint Inhibitors (ICIs), particularly anti-PD-1 and anti-CTLA-4 therapies, have further enhanced interest in melanoma vaccines by helping overcome tumor-induced immune suppression and augment T-cell activation.<\/jats:p>\n                  <jats:p>\n                    In addition to reviewing vaccine mechanisms and emerging technologies, this manuscript examines the evolving clinical trial landscape through analysis of melanoma vaccine studies registered on\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                    . Although many studies have reported encouraging safety and immunogenicity findings, challenges related to tumor heterogeneity, immune evasion, biomarker selection, and manufacturing complexity continue to limit widespread clinical implementation.\n                  <\/jats:p>\n                  <jats:p>Ongoing advances in computational immunology, biomaterial engineering, and precision oncology are expected to further refine melanoma vaccine development and improve therapeutic efficacy. Collectively, these innovations may help establish melanoma vaccines as an increasingly important component of future personalized cancer immunotherapy strategies.<\/jats:p>","DOI":"10.1177\/25151355261488241","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T16:09:51Z","timestamp":1788970191000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic melanoma vaccines: Platforms, neoantigen strategies, and emerging combination immunotherapies"],"prefix":"10.1177","volume":"14","author":[{"given":"Daniel","family":"Mhanna","sequence":"first","affiliation":[{"name":"University of Balamand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilal","family":"Salman","sequence":"additional","affiliation":[{"name":"University of Balamand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawad","family":"El Hakim","sequence":"additional","affiliation":[{"name":"University of Balamand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Aridi","sequence":"additional","affiliation":[{"name":"University of Balamand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wissam","family":"Abou Ali","sequence":"additional","affiliation":[{"name":"University of Balamand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilal","family":"Al Halabi","sequence":"additional","affiliation":[{"name":"University of Balamand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Faour","sequence":"additional","affiliation":[{"name":"University of Balamand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Harb","sequence":"additional","affiliation":[{"name":"University of Balamand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Azar","sequence":"additional","affiliation":[{"name":"University of Balamand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7983-2090","authenticated-orcid":false,"given":"Hilda E.","family":"Ghadieh","sequence":"additional","affiliation":[{"name":"University of Balamand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.15586\/codon.cutaneousmelanoma.2017.ch1"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.0160"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.soc.2025.01.004"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.32604\/or.2025.063843"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms251810120"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-025-00969-1"},{"key":"e_1_3_5_8_2","first-page":"237","article-title":"Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma","volume":"11","author":"Kim T","year":"2014","unstructured":"Kim T, Amaria RN, Spencer C, et al. Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma. Cancer Biol Med 2014; 11: 237\u2013246. https:\/\/doi.org\/10.7497\/j.issn.2095-3941.2014.04.002","journal-title":"Cancer Biol Med"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2019.02.002"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000535"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1006665"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01270-x"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.17305\/bb.2024.11069"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.944722"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1438106"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13236061"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13010098"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01460-0"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01062-w"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1604958"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406498"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aak9702"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14069"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14824"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2016.72"},{"key":"e_1_3_5_26_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/ol.2020.12097","article-title":"Targeting tumor-associated macrophages in the tumor microenvironment","volume":"20","author":"Zhou K","year":"2020","unstructured":"Zhou K, Cheng T, Zhan J, et al. Targeting tumor-associated macrophages in the tumor microenvironment. Oncol Lett 2020; 20: 1\u20131, (Review). https:\/\/doi.org\/10.3892\/ol.2020.12097","journal-title":"Oncol Lett"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature22991"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13025"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-814039-0.00009-6"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cgt.7700961"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2007.06179.x"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2023.189068"},{"key":"e_1_3_5_33_2","first-page":"137","volume-title":"Advances in Immunology","year":"2025","unstructured":"2025) Personalized precision: Revolutionizing cancer treatment with mRNA-based vaccines in melanoma therapy. In: Advances in Immunology. Elsevier, pp 137\u2013167."},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14205163"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsbiomaterials.5c01698"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11538-025-01462-w"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nwnano.2025.100147"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17437"},{"key":"e_1_3_5_39_2","doi-asserted-by":"publisher","DOI":"10.3109\/14653241003774045"},{"key":"e_1_3_5_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00902-1"},{"key":"e_1_3_5_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115361"},{"key":"e_1_3_5_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-025-09725-3"},{"key":"e_1_3_5_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11596-025-00112-5"},{"key":"e_1_3_5_44_2","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000003455"},{"key":"e_1_3_5_45_2","doi-asserted-by":"publisher","DOI":"10.1201\/9781003501718"},{"key":"e_1_3_5_46_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.923647"},{"key":"e_1_3_5_47_2","doi-asserted-by":"publisher","DOI":"10.1201\/9781003503071"},{"key":"e_1_3_5_48_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.922301"},{"key":"e_1_3_5_49_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01807-w"},{"key":"e_1_3_5_50_2","doi-asserted-by":"publisher","DOI":"10.1080\/17435889.2024.2419815"},{"key":"e_1_3_5_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2024.11.015"},{"key":"e_1_3_5_52_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16040455"},{"key":"e_1_3_5_53_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16010059"},{"key":"e_1_3_5_54_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1448489"},{"key":"e_1_3_5_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2025.115675"},{"key":"e_1_3_5_56_2","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12080950"},{"key":"e_1_3_5_57_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.696791"},{"key":"e_1_3_5_58_2","doi-asserted-by":"publisher","DOI":"10.2174\/092986709789909648"},{"key":"e_1_3_5_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2019.01.007"},{"key":"e_1_3_5_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110721"},{"key":"e_1_3_5_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biotechadv.2015.10.013"},{"key":"e_1_3_5_62_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4471-4372-7_17"},{"key":"e_1_3_5_63_2","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.12933"},{"key":"e_1_3_5_64_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12033-025-01519-0"},{"key":"e_1_3_5_65_2","doi-asserted-by":"publisher","DOI":"10.21315\/mjms2024.31.6.2"},{"key":"e_1_3_5_66_2","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11020280"},{"key":"e_1_3_5_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2005.01.013"},{"key":"e_1_3_5_68_2","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181cf23a6"},{"key":"e_1_3_5_69_2","doi-asserted-by":"publisher","DOI":"10.1002\/vms3.65"},{"key":"e_1_3_5_70_2","doi-asserted-by":"publisher","DOI":"10.1186\/2051-1426-1-20"},{"key":"e_1_3_5_71_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12060540"},{"key":"e_1_3_5_72_2","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2023.2292772"},{"key":"e_1_3_5_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2019.102114"},{"key":"e_1_3_5_74_2","doi-asserted-by":"publisher","DOI":"10.1159\/000537896"},{"key":"e_1_3_5_75_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40588-025-00251-2"},{"key":"e_1_3_5_76_2","doi-asserted-by":"publisher","DOI":"10.4161\/21645515.2014.980686"},{"key":"e_1_3_5_77_2","doi-asserted-by":"publisher","DOI":"10.2165\/00124363-200519010-00004"},{"key":"e_1_3_5_78_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-814039-0.00010-2"},{"key":"e_1_3_5_79_2","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1433516"},{"key":"e_1_3_5_80_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2017.02.016"},{"key":"e_1_3_5_81_2","doi-asserted-by":"publisher","DOI":"10.1177\/1535370216643771"},{"key":"e_1_3_5_82_2","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1330236"},{"key":"e_1_3_5_83_2","doi-asserted-by":"publisher","DOI":"10.2174\/156652311798192815"},{"key":"e_1_3_5_84_2","doi-asserted-by":"publisher","DOI":"10.4161\/hv.4.6.6200"},{"key":"e_1_3_5_85_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.09.062"},{"key":"e_1_3_5_86_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2016.01.054"},{"key":"e_1_3_5_87_2","doi-asserted-by":"publisher","DOI":"10.2174\/1566523214666140522121427"},{"key":"e_1_3_5_88_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00705-017-3230-7"},{"key":"e_1_3_5_89_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2012.055"},{"key":"e_1_3_5_90_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2012.10.003"},{"key":"e_1_3_5_91_2","doi-asserted-by":"publisher","DOI":"10.2174\/1570162053506937"},{"key":"e_1_3_5_92_2","doi-asserted-by":"publisher","DOI":"10.4161\/hv.4.6.6179"},{"key":"e_1_3_5_93_2","doi-asserted-by":"publisher","DOI":"10.2741\/2371"},{"key":"e_1_3_5_94_2","doi-asserted-by":"publisher","DOI":"10.1081\/CNV-120025091"},{"key":"e_1_3_5_95_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-013-0030-9"},{"key":"e_1_3_5_96_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.117858"},{"key":"e_1_3_5_97_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22626"},{"key":"e_1_3_5_98_2","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0b013e32834b58fa"},{"key":"e_1_3_5_99_2","doi-asserted-by":"publisher","DOI":"10.2217\/imt.12.94"},{"key":"e_1_3_5_100_2","doi-asserted-by":"publisher","DOI":"10.3390\/cimb47100806"},{"key":"e_1_3_5_101_2","doi-asserted-by":"publisher","DOI":"10.4014\/jmb.2506.06021"},{"key":"e_1_3_5_102_2","doi-asserted-by":"publisher","DOI":"10.1002\/9781394271566.ch10"},{"key":"e_1_3_5_103_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4614-7147-9_39"},{"key":"e_1_3_5_104_2","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1056974"},{"issue":"7","key":"e_1_3_5_105_2","first-page":"7277","article-title":"Revolutionizing Cancer Treatment: Unleashing the Power of Viral Vaccines, Monoclonal Antibodies, and Proteolysis-Targeting Chimeras in the New Era of Immunotherapy","volume":"9","author":"Mohite P","year":"2024","unstructured":"Mohite P, Yadav V, Pandhare R, et al. Revolutionizing Cancer Treatment: Unleashing the Power of Viral Vaccines, Monoclonal Antibodies, and Proteolysis-Targeting Chimeras in the New Era of Immunotherapy. ACS Omega 2024; 9(7): 7277\u20137295. acsomega.3c06501. https:\/\/doi.org\/10.1021\/acsomega.3c06501","journal-title":"ACS Omega"},{"key":"e_1_3_5_106_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.70006"},{"key":"e_1_3_5_107_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bulcan.2025.02.012"},{"key":"e_1_3_5_108_2","doi-asserted-by":"publisher","DOI":"10.1111\/jebm.70116"},{"key":"e_1_3_5_109_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.27640"},{"key":"e_1_3_5_110_2","first-page":"117","volume-title":"Advances in Immunology","author":"Prabhakar PK","year":"2025","unstructured":"Prabhakar PK, Upadhyay TK, Sahu SK. mRNA-based cancer vaccines: A novel approach to melanoma treatment. In: Advances in Immunology. Elsevier, 2025, pp. 117\u2013162."},{"key":"e_1_3_5_111_2","doi-asserted-by":"publisher","DOI":"10.2174\/1568026615666150812121439"},{"key":"e_1_3_5_112_2","doi-asserted-by":"publisher","DOI":"10.11569\/wcjd.v16.i15.1597"},{"key":"e_1_3_5_113_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15041106"},{"key":"e_1_3_5_114_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10517-026-06645-6"},{"key":"e_1_3_5_115_2","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2016-0002"},{"key":"e_1_3_5_116_2","doi-asserted-by":"publisher","DOI":"10.3390\/cells9112432"},{"key":"e_1_3_5_117_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.08.053"},{"key":"e_1_3_5_118_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.4401"},{"key":"e_1_3_5_119_2","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1992880"},{"key":"e_1_3_5_120_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-017-9656-2"},{"key":"e_1_3_5_121_2","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000245"},{"key":"e_1_3_5_122_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-025-04143-9"},{"key":"e_1_3_5_123_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0217762"},{"key":"e_1_3_5_124_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02268-7"},{"key":"e_1_3_5_125_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-025-01574-6"},{"key":"e_1_3_5_126_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-1922"},{"key":"e_1_3_5_127_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.suronc.2024.102160"},{"key":"e_1_3_5_128_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00044"},{"key":"e_1_3_5_129_2","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1792058"},{"key":"e_1_3_5_130_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2024.100726"},{"key":"e_1_3_5_131_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-016-0693-8"},{"key":"e_1_3_5_132_2","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181a95165"},{"key":"e_1_3_5_133_2","doi-asserted-by":"publisher","DOI":"10.34172\/bma.62"},{"key":"e_1_3_5_134_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18010144"},{"key":"e_1_3_5_135_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01807"},{"key":"e_1_3_5_136_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1054231"},{"key":"e_1_3_5_137_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102575"},{"issue":"1","key":"e_1_3_5_138_2","first-page":"245","article-title":"The anti-tumor immune response induced by a combination of MAGE-3\/MAGE-n-derived peptides","volume":"20","author":"Zhang X-M","year":"2008","unstructured":"Zhang X-M, Zhang Y-F, Huang Y, et al. The anti-tumor immune response induced by a combination of MAGE-3\/MAGE-n-derived peptides. Oncol Rep 2008; 20(1): 245\u2013252. https:\/\/doi.org\/10.3892\/or.20.1.245","journal-title":"Oncol Rep"},{"key":"e_1_3_5_139_2","doi-asserted-by":"publisher","DOI":"10.1517\/14728214.10.2.393"},{"key":"e_1_3_5_140_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.136252"},{"key":"e_1_3_5_141_2","doi-asserted-by":"publisher","DOI":"10.37349\/etat.2025.1002350"},{"key":"e_1_3_5_142_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2026.1766201"},{"key":"e_1_3_5_143_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1478201"},{"key":"e_1_3_5_144_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13721-025-00674-3"},{"key":"e_1_3_5_145_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2026.1727976"},{"key":"e_1_3_5_146_2","unstructured":"Efficacy and Safety of UV1 Vaccination in Combination With Nivolumab and Ipilimumab as First Line Treatment of Patients With Unresectable or Metastatic Melanoma (INITIUM Study). 2020."},{"key":"e_1_3_5_147_2","unstructured":"A Prospective Randomized Blinded Placebo-controlled Phase IIb Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine vs Unloaded YCWP + DC and Embedded Phase I\/IIa Trial With Tumor Lysate Particle Only (TLPO) Vaccine in Stage III and Stage IV (Resected) Melanoma to Prevent Recurrence. 2014."},{"key":"e_1_3_5_148_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.9589"},{"key":"e_1_3_5_149_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1023023"},{"key":"e_1_3_5_150_2","unstructured":"Phase 1 Study Using a Plasmid DNA Coding for Emm55 Streptococcal Antigen in Patients With Unresectable Stage III or Stage IV Cutaneous Melanoma. 2018."},{"key":"e_1_3_5_151_2","unstructured":"Mature Dendritic Cell Vaccination Against Mutated Antigens in Patients With Advanced Melanoma. 2017."},{"key":"e_1_3_5_152_2","unstructured":"A Trial to Evaluate the Safety Immunogenicity and Clinical Activity of a Helper Peptide Vaccine Plus PD-1 Blockade. 2015."},{"key":"e_1_3_5_153_2","unstructured":"Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs Esophagus Pleura or Mediastinum. 2014."},{"key":"e_1_3_5_154_2","unstructured":"A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy. 2015."},{"key":"e_1_3_5_155_2","unstructured":"Combination Therapy With Nivolumab and PD-L1\/IDO Peptide Vaccine to Patients With Metastatic Melanoma. 2017."},{"key":"e_1_3_5_156_2","unstructured":"A Trial to Evaluate the Immunogenicity and Safety of a Melanoma Helper Peptide Vaccine Plus Novel Adjuvant Combinations (MEL63). 2015."},{"key":"e_1_3_5_157_2","unstructured":"Multi-center Phase I\/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease. 2016."},{"key":"e_1_3_5_158_2","unstructured":"Open Label Randomized Phase I\/II Study of a Long Peptide Vaccine Plus TLR Agonists for Resected Stage IIb-IV Melanoma. (MEL60). 2014."},{"key":"e_1_3_5_159_2","unstructured":"Randomized Phase II Study of Multipeptide Vaccination With or Without Regulatory T Cell Depletion Using Ontak in Patients With Metastatic Melanoma. 2007."},{"key":"e_1_3_5_160_2","unstructured":"Phase I Study of NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma for Whom Treatment With Ipilimumab is Indicated. 2013."},{"key":"e_1_3_5_161_2","unstructured":"Vaccination of Melanoma Patients (Stage II-IV) With ImmuFact IMP321 Tumor Antigenic Peptides and Montanide. 2011."},{"key":"e_1_3_5_162_2","unstructured":"Study of GSK2302025A Antigen-Specific Cancer Immunotherapeutic in Patients With Metastatic Melanoma. 2010."},{"key":"e_1_3_5_163_2","unstructured":"Adoptive Transfer of MART-1 F5 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) After a Nonmyeloablative Conditioning Regimen With Administration of MART-126\u202235-Pulsed Dendritic Cells and Interleukin-2 in Patients With Advanced Melanoma. 2009."},{"key":"e_1_3_5_164_2","unstructured":"A Phase II Study of the Clinical and Immunological Effects of NY-ESO-1 ISCOM\u00ae Vaccine in Patients With Measurable Stage III and IV Malignant Melanoma. 2007."},{"key":"e_1_3_5_165_2","unstructured":"A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen. 2008."},{"key":"e_1_3_5_166_2","unstructured":"Randomized Double-blind Phase II Trial of NY-ESO-1 ISCOMATRIX\u00ae Vaccine and ISCOMATRIX\u00ae Adjuvant Alone in Patients With Resected Stage Ilc Illb lIIc or IV Malignant Melanoma. 2005."},{"key":"e_1_3_5_167_2","unstructured":"Phase I\/II Study of Immunization With Multiple Peptides Mixed With the Immunological Adjuvant CpG 7909 or Montanide ISA51 in HLA-A2 Patients With Metastatic Cutaneous Melanoma. 2005."},{"key":"e_1_3_5_168_2","unstructured":"NY-ESO-1 Protein Vaccination in Malignant Melanoma Administered With Imiquimod as Adjuvant. 2005."},{"key":"e_1_3_5_169_2","unstructured":"A Multicenter Trial to Evaluate the Effects of Administration of Cyclophosphamide and Melanoma-Derived Helper Peptides on the Immunogenicity of a Class I MHC-Restricted Peptide-Based Vaccine in Participants With Resected Melanoma. 2005."},{"key":"e_1_3_5_170_2","unstructured":"A Randomized Phase II Trial of Multi-Epitope Vaccination With Melanoma Peptides For Cytotoxic T Cells And Helper T Cells For Patients With Metastatic Melanoma. 2003."},{"key":"e_1_3_5_171_2","unstructured":"Vaccination of Patients With Stage III or IV Malignant Melanoma With Melanoma Antigen Peptides [Melan-A\/Mart-1 Analog (ELA) NY-ESO-1b(A) Analog and MAGE-A10] and Montanide Adjuvant. 2005."},{"key":"e_1_3_5_172_2","unstructured":"A Multicenter Double-blind Placebo-controlled Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence. 2012."},{"key":"e_1_3_5_173_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1698503"},{"key":"e_1_3_5_174_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1336023"},{"key":"e_1_3_5_175_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17111882"},{"key":"e_1_3_5_176_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-024-01436-7"},{"key":"e_1_3_5_177_2","doi-asserted-by":"publisher","DOI":"10.2217\/mmt-2016-0014"},{"key":"e_1_3_5_178_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-67508-8"},{"key":"e_1_3_5_179_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1808146"},{"key":"e_1_3_5_180_2","doi-asserted-by":"publisher","DOI":"10.1080\/23723556.2026.2652613"},{"key":"e_1_3_5_181_2","doi-asserted-by":"publisher","DOI":"10.3390\/cells15030298"},{"key":"e_1_3_5_182_2","doi-asserted-by":"publisher","DOI":"10.3390\/cells14181476"},{"key":"e_1_3_5_183_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature23003"},{"key":"e_1_3_5_184_2","doi-asserted-by":"publisher","DOI":"10.3390\/cells15020099"},{"key":"e_1_3_5_185_2","doi-asserted-by":"publisher","DOI":"10.37349\/etat.2025.1002313"},{"key":"e_1_3_5_186_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-013035"},{"key":"e_1_3_5_187_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102962"},{"key":"e_1_3_5_188_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2537-9"},{"key":"e_1_3_5_189_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1172913"},{"key":"e_1_3_5_190_2","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2016-0009"},{"key":"e_1_3_5_191_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.116359"},{"key":"e_1_3_5_192_2","first-page":"641","article-title":"Human papillomavirus-associated skin cancers among organ transplant recipients: A systematic review and meta-analysis","volume":"16","author":"Faraji N","year":"2025","unstructured":"Faraji N, Farokhi S, Fakouri A, et al. Human papillomavirus-associated skin cancers among organ transplant recipients: A systematic review and meta-analysis. Casp J Intern Med 2025; 16: 641\u2013650. https:\/\/doi.org\/10.22088\/cjim.16.4.641","journal-title":"Casp J Intern Med"},{"key":"e_1_3_5_193_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2026.218359"},{"key":"e_1_3_5_194_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf327"},{"key":"e_1_3_5_195_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-026-01199-1"},{"key":"e_1_3_5_196_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02575"}],"container-title":["Therapeutic Advances in Vaccines and Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/25151355261488241","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/25151355261488241","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/25151355261488241","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T10:51:23Z","timestamp":1789210283000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/25151355261488241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":195,"alternative-id":["10.1177\/25151355261488241"],"URL":"https:\/\/doi.org\/10.1177\/25151355261488241","relation":{},"ISSN":["2515-1355","2515-1363"],"issn-type":[{"value":"2515-1355","type":"print"},{"value":"2515-1363","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"article-number":"25151355261488241"}}